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Summary-Ethyl carbamate is found in fermented foods: bread contains 3-15 ng/g, stone-fruit brandies 
200-20,000 ngfg, and about one-third of table-wine samples analysed contained more than 10 ng/g. In 
animals, ethyl carbamate is degraded to C02, H20 and NH3, with intermediate formation ofethanol. This 
degradation has been shown tobe inhibited (postponed) in the mouse by ethanol concentrations in the 
blood of about 0.15% and higher. A quantitatively minor pathway involves a two-step oxidation of the 
ethyl group to vinyl carbamate and epoxyethyl carbamate, the postulated electrophilic moiety that reacts 
with DNA. This reaction is probably the mode of the mutagenic action observed in many cellular and 
animal systems. The fact that only vinyl carbamate, but not ethyl carbamate, is mutagenic in a standard 
Ames test is probably because there is insufficient production of the intermediate oxidation product in 
the standard test. Consistent with this metabolism is the carcinogenic activity of ethyl carbamate in various 
animal species and in different organs; this activity can be seen even after a single high dose in early life. 
Quantitative analysis of the total tumour incidences after chronic exposure of rats and mice to 0.1-12.5 mg 
ethyl carbamate/kg body weightjday in the drinking-water showed a dose-related increase. The main target 
organs were the mammary gland (female rats and mice having similar susceptibilities) and the Jung (mice 
only). On the basis of sex- and organ-specific tumour data and with a linear extrapolation to a negligible 
increase of the lifetime tumour incidence by 0.0001% ( one additional tumour in one milüon individuals 
exposed for life), a "virtually safe dose .. of 20 to 80 ng/kg body weight/day was estimated. The daily 
burden reached under normal dietary habits without alcoholic beverages is in the range of about 20 ng/kg 
body weightfday. Regular table-wine consumption would increase the risk by a factor of up to five. 
Regular drinking of 20 to 40 ml stone-fruit brandy per day could raise the calculated lifetime tumour risk 
to near 0.01%. 
Introduction 
Ethyl carbamate (urethan[e]; NH2COOCH2CH3) has 
a wide spectrum of biological activities (for reviews 
see Boyland, 1968; Field and Lang, 1988). In the 
1940s, ethyl carbamate was used as a hypnotic in man 
at doses of 1 g/person/day and as an anaesthetic for 
Iabaratory animals. In 1943, it was discovered that 
ethyl carbamate has a carcinogenic effect in animals. 
Three years later, its activity against leukaemia in 
man was described, and since 1948 it has been known 
that ethyl carbamate is mutagenic in Drosophila 
melanogaster. 
Today, humans are exposed to ethyl carbamate in 
food and alcoholic beverages. Under normal dietary 
habits, excluding alcohol, Zimmerli et a/. (1986) 
estimated a daily ethyl carbamate intake for adults 
of the order of 20 ng/kg body weight, with bread 
assumed to be the main source (mean concentration 
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7 ng/g, range 3 to 15 ng/g. Three years ago it was 
reported that stone-fruit brandies can contain large 
amounts of ethyl carbamate (average concentration 
1500 ng/g, range 200 to 20,200 ngjg; Anonymous, 
1986). Regular daily consumption of as little as 7 ml 
stone-fruit brandy can Iead to a ten-fold increase in 
ethyl carbamate intake based on normal dietary 
habits. 
The mechanism of formation of ethyl carbamate in 
such spirits has been investigated (Battaglia et al., 
1988; Baumann and Zimmerli, 1987 and 1988). From 
these studies it can be deduced that ethyl carbamate 
is formed from natural components, most probably 
by reaction of ethanol with isocyanic acid, an oxi-
dation product of cyanide that is a weil known 
constituent of stone fruits. This formation pathway 
shows a strong dependence on exposure to (sun)light 
(Baumann and Zimmerli, 1988). 
Recent analytical data have demonstrated that 
ethyl carbamate is also fonned in table wine. Prelimi-
nary analytical data show that Ievels above 10 ng/g 
are found in about one-third of the analysed samples 
(Mitchell and Jacobson, 1987; B. Zimmerli, personal 
communication, 1989). Here, the mechanism of 
formation of ethyl carbamate probably involves 
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urea (Ough et al., 1988), a degradation product 
of arginine, either directly or after temperature-
rlependent deamination to isocyanic acid. 
Todetermine whether ethyl carbamate represents a 
possible health hazard at low exposure Ievels, it is 
important to characterize the toxic potential of this 
compound, including its mechanism of action. In this 
context, the acute toxicity of ethyl carbamate can be 
neglected since it is relatively low, of the order of 
2500 mg/kg body weight (LD50 rat, oral administra-
tion; NIOSH, 1985). 
Pharmacokinetics and metabolism 
In rats and mice, ethyl carbarnate is rapidly dis-
tributed throughout the body irrespective of the route 
of administration. In mice, following injection of 
[carbony/.I4C] Iabelied or [methylene-' 4C]-label1ed 
ethyl carbamate, about 90% of the compound is 
completely degraded to C02 , H20 and NH3 within 
24 hr as detected by exhaled radio Iabelied co2. 
About equal amounts, of up to 6%, are either 
excreted in the urine mainly as metabolites (see 
below) or appear to remain in the body (for reviews 
see IARC, 1974; Mirvish, 1968). 
O'Flaherty and Sichak (1983) found evidence of 
saturation of metabolism in male outbred Swiss mice 
at all dose Ievels investigated (0.4-1.8 gfkg body 
weight, ip). In a recent investigation, saturation was 
reported to occur in male Fischer 344 rats at iv doses 
above 4.75 mg/kg body weight and in male B6C3F1 
mice above 47.5 mgfkg body weight (Nomeir et al., 
I 989). This demonstrates large species differences and 
a relatively low capacity to clear ethyl carbamate 
from the body. 
lf ethyl carbamate is given to pregnant mice, the 
substance crosses the placental barrier. In newborn 
mice, the elimination of ethyl carbamate is even 
slower than in the adult mouse: only 20% of the 
administered dose is metabolized after 24 hr (IARC, 
1974). 
In rats, rabbits and humans (early chemotherapy 
of patients with multiple myeloma) the urinary 
metabolites as a percentage of the administered 
dose are: 0.5-1.7% unchanged ethyl carbarnate, 
0.02--0.15% N-hydroxy ethyl carbamate, 0.1--0.6% 
N -acetyl-N -hydroxy ethyl carbamate, 0.1-0.2% ethyl 
mercapturic acid and 0.9-2.1% N -acetyl-S -ethoxy 
carbonylcysteine. These metabolites represent rninor 
pathways, the major one, as already mentioned, Ieads 
to complete degradation, with ethanol as an interme-
diate from ester bond cleavage (IARC, 1974; Mirvish, 
1968). 
In an in vitro study, Gupta and Dani (1989) 
incubated ethyl carbarnate with microsornes from the 
liver, 1ung, brain and kidneys of the rat. Three 
metabolites were found using thin-layer chromatog-
raphy: N -hydroxyethyl carbamate, N -hydroxy vinyl 
carbamate, epoxyethyl carbamate, when incubated 
with lung microsomes but not when incubated with 
microsomes from other organs (no data on the 
detection Iimit of the metabolites were given). This 
demonstrated the occurrence of oxidation reactions 
at the ethyl group. The vinyl carbamate and its epoxy 
derivative generated may represent the proximate and 
ultimate electrophilic metabolites responsible for 
genotoxicity and carcinogenicity. 
The observed organ specificity in vitro noted above 
is not consistent with the susceptibility to tumour 
induction: while the lung is the main target organ for 
tumours in mice, it is not in rats (see below). The 
possibility of more active detoxication pathways in 
vivo (e.g. involving epoxide hydrolase; Vogel-Bindei 
et al., 1982) may provide an explanation for this 
inconsistency. 
As human exposure to higher Ievels of ethyl carba-
mate results from consumption of alcoholic bever-
ages, the interaction of ethyl carbamate with ethanol 
may be important. The effects of a single high dose 
of ethanol (5 g/kg body weight, initial blood ethanol 
Ievel of about 0.48%) on the metabolism of [ethy/-l-
14C]ethyl carbamate (11.1 mg/kg body weight) has 
recently been investigated in the mouse (Waddell et 
a/., 1987; Yamamoto et a/., 1988). Under these 
conditions, a high, constant blood 1evel of ethyl 
carbamate persisted for 8 hr after oral administration 
and declined only thereafter. This was paralleled by 
a 1arge decrease in the rate of 14C02 expiration during 
these 8 hr followed by an increase thereafter. This 
suggests an inhibition of metabolism of ethyl carba-
mate by higher blood ethanollevels (>0.15o/o). With-
out ethanol, ethyl carbamate (radioactivity) almost 
completely disappeared from the blood within 4 
hours. The authors concluded ... "that coadminis-
tration of ethanol or other alcohols may inhibit the 
carcinogenic action of urethane and other com-
pounds" (Yamamoto et al., 1988). However, the cited 
investigation on1y shows that acute administration of 
high doses of ethanol may postpone the metabolism 
of ethyl carbamate, possibly by blocking metabo1iz-
ing enzymes, including the group of cytochromes 
P-450. This may indeed influence the carcinogenic 
action of ethyl carbamate (see below) but it may also 
Iead to a shift in organotropy to tissues where the 
P-450 isoenzymes are not inhibited to the same 
degree. This phenomenon is weil known for the 
interaction of ethanol with the activation of other 
carcinogens such as nitrosamines (IARC 1988; 
Swann, 1984). In addition, very little ethyl carbamate 
is excreted during the inhibition of metabolism by 
ethanol. The toxic effects might, therefore, merely be 
postponed. It should also be kept in mind that 
chronic administration of ethanol, in contrast to the 
acute situation, may Iead to induction of metaboliz-
ing enzyme systems such as P-450 (Lieber et al., 
1987a,b) and thus modulate the carcinogenicity of 
ethyl carbamate. It is interesting to note that ethanol 
is formed as a cleavage product of the ester bond of 
ethyl carbamate itself. Mirvish ( 1968) reported that 
degradation of ethyl carbamate was inhibited up to 
90% by blocking esterase activity, which indicates 
that ethanol may be formed in near equimolar 
amounts to the administered ethyl carbamate dose. 
It remains to be shown whether the ethanol thus 
formed can modulate the further metabolism of ethyl 
carbamate. 
Mutagenicity 
Vogt ( 1948) described ethy1 carbamate as a chro-
mosome-breaking agent able to induce the same types 
of mutations in Drosophila as are induced by differ-
ent types of irradiation or mustard gas. Many studies 
have been published concerning the mutagenicity 
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of ethyl carbamate in a wide range of organisms, 
including plants (for an overview see Bateman, I 976; 
deSerres and Ashby, 1981; Field and Lang, 1988; 
Kada and Ishidate, 1980). In bacterial test systems 
the results were mainly negative. An explanation for 
this may be that in the standard Salmonella/ 
microsome assay, using rat-liver S-9, there is insuffi-
cient oxidation of ethyl carbamate to vinyl carbamate 
(the first step in the metabolic activation) to give 
positive results. The fact that vinyl carbamate gives 
positive results in the Ames test (Dahl et a/., 1980) 
strongly supports this hypothesis. 
In tests with eukaryotic cells, positive and negative 
findings are about equal in frequency. It seems that 
positive results have been obtained only under con-
ditions of appropriate metabolic activation. At this 
Institute, ethyl carbamate was tested for mutagenicity 
in the somatic mutation and recombination test in 
Drosophila melanogaster (number and shape of wing 
hairs after treatment of larvae), using a standard 
strain and a strain in which genetic control of the 
cytochrome P -450-dependent enzyme systems has 
been altered by su bstituting the first and second 
chromosome by those of a wild type, DDT-resistant 
strain with constitutively increased P-450 enzyme 
activities (Frölich, 1989; Frölich and Würgler, 1988). 
A dose-dependent increase in the genotoxic activity 
of ethyl carbamate was observed. The frequency of 
induction of mutations in the modified strain with 
increased P -450 enzyme activities was increased by 
about one order of magnitude compared with the 
standard strain. This further suggests that the P -450 
enzyme system is invoJved in the activation of etbyl 
carbamate. 
DNA-adduct formation 
It is often extremely difficult or even impossible to 
extrapolate the data from in vitro mutagenicity testing 
(e.g. in systems like the Ames test) to a genotoxic 
potency in vivo in a quantitative manner. In contrast, 
DNA-adduct formation determined in vivo in the 
target tissue appears to represent a good measure of 
the biologically effective dose ( deSerres, 1988; Lutz, 
1979). With ethyl carbamate, more than ten publi-
cations give quantitative data on adduct formation, 
mainly in mice but also in rats. All tissues investigated 
showed DNA adducts. The Jiver almost always 
bad the highest values, a few hours after single-
dose administration (Fossa et al., 1985; Lutz, 1979; 
Scherer et al., 1986; Svensson, 1988). For the lung, 
DNA-binding potency appeared to be about one 
order of magnitude below the .value determined for 
the liver (Fossa et al., 1985). The Ievel of DNA-
adduct formation for the dose administered places 
ethyl carbamate amongst the moderately potent 
genotoxic (hepato) carcinogens, a factor of 1 00 to 
1000 below the carcinogenic potency of aflatoxin 8 1 
and a factor of ten below the potency of vinyl 
chloride. 
Several authors proposed a metabolic pathway 
that Ieads to the formation of vinyl carbamate and, 
after epoxidation, to DNA and RNA adducts (Miller 
and Miller, 1983; Ribovich et a/., 1982). Recently, 
this hypothesis has been supported by the study of 
Gupta and Dani (1989), who identified N -hydroxy 
vinyl carbamate and an epoxy derivative of ethyl 
carbamate as metabolites. Furthermore, 7-(2-
oxoethyl)guanine was identified as a DNA adduct in 
mouse and rat liver after injection of Iabelied ethyl 
carbamate (Miller and Miller, 1983; Scherer et al., 
1986). In addition, vinyl carbamate was shown to 
Iead to the same DNA adducts as ethy1 carbamate, 
although the potency of the fonner was much higher 
(Scherer et a/., 1986). 
Since 7-(2-oxoethyl)guanine is also formed by vinyJ 
chloride (Laib et al., 1981), Svensson (1988) postu-
lated a common ultimate carcinogen for the two 
compounds and compared their potency to form 
DNA-adducts with their respective carcinogenic po-
tencies. This quantitative comparison revealed a good 
correlation of the ethyl carbamate data with the vinyl 
chloride data. 
Carcinogenicity 
The data discussed above indicate that ethyl carba~ 
mate is genotoxic in vitro and in vivo. lt is therefore 
not surprising that this compound is also reported to 
be carcinogenic. There is a vast Iiterature on ethyl 
carbamate carcinogenicity (IARC, 1974; Mirvish, 
1968; National Cancer Institute, 1978 and 1980). The 
following Iist is a summary derived from th.e data 
reviewed in IARC (1974); Doses of 100-2000 mg 
ethyl carbamate/kg body weight, typically a single 
dose of 1000 mg/kg body weight, have been shown to 
induce tumours in rats, mice and hamsters after 
administration by inhalation or by oral, dermal, 
subcutaneous or intraperitoneal routes. A tumour 
incidence of 40-100% is typical after administration 
of 100-1000 mg ethyl carbamate/kg body weight in 
the drinking-water, depending on the duration of 
treatment. A high tumour incidence (80-1 00% lung 
tumours) was also found in newborn mice after a 
single "standard" dose of 1000 mg ethyl carba-
mate/kg body weight given by oral gavage. When 
pregnant mice were given a single intraperitoneal 
injection of this "standard" dose one day before 
delivery, 100% of the offspring developed lung tu-
mours within 6 months (9-10 tumours per mouse). 
Tumour induction in offspring was also demon-
strated when ethyJ carbamate was administered to 
lactating mice. 
At present, only two experimental carcinogenicity 
studies with doses in the 1ower mg/kg body weight 
range are available in the Iiterature (a further carcino~ 
genicity study is currently being conducted in the 
National Toxicology Program; Food Chemical 
News, 1988). In the first study (Dahl et al., 1980), 
newborn mice were injected intraperitoneally twice a 
week with 0, 4.1, 8.2, 12.1 or 501.2 mg ethyl carba-
mate/kg body weight for 4 weeks and rats were 
similarly injected twice a week with 0, 8.2 or 300 mg 
ethyl carbamatefkg body weight for 5 weeks. A 
dose-dependent increase in tumour frequency was 
found in the lung (mice only) ~md the liver (thymoma 
and Harderian gland tumours were also found). Liver 
tumour incidences were, in male mice, 24, 56, 88, 88 
and 100% and in female mice, 0, 9, 27, 35 and 70%, 
for groups given 0, 4.1, 8.2, 12.1 and 501.2 mgjkg, 
respectively. In male rats the liver tumour incidences 
were 0, 15 and 28%, and in female rats 0, 9 and 
47% for the groups given 0, 8.2 and 300 mg/kg, 
respectively. As ethyl carbamate administration was 
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restricted to eight or ten injections, this study is 
unsuitable for risk assessment in humans. 
In the second study (Port et al., 1976, Schmäht et 
al., 1977), 8-wk-old Sprague-Dawley rats and NMRI 
mice were exposed to 0, 0.1, 0.5, 2.5 or 12.5 mg ethyl 
carbamate/kg body weight/day in the drinking-water 
for up to 2 years. Again, dose-dependent increases in 
tumour incidence were found in certain organs. How-
ever, the quantitative data were reported as tumour 
incidences pooled for all organs. The sex-specific and 
target organ-specific data have now been compiled 
from original data kindly provided by Dr R. Port 
(German Cancer Research Center, Heidelberg, per-
sonal communication, 1989). In the rat, females 
exposed to the higher doses showed increased tumour 
incidences in the mammary gland (Table 1). At 
12.5 mg/kg body weight/day the incidence of mam-
mary tumours was 24% (9/38) compared with 0% 
(0/36) in the controls. There was no organ-specific 
increase in tumour incidence in male rats. In female 
mice a dose-dependent increase in the incidence of 
benign and malignant mammary tumours was also 
seen (6/33 at 12.5 mg/kg compared with 0/38 in the 
control group ). In addition, both male and female 
mice showed an increased incidence of benign and 
malignant Jung tumours (Table 1); at 12.5 mg/kg 
males and females showed incidences of 5/32 and 
10/33, respectively, while there were no Jung tumours 
in the control groups. At 2.5 mg/kg, only the males 
bad an increased lung-tumour incidence (4/28). 
Two Russian studies reported by IARC (1988) 
investigated the interaction of ethyl carbamate and 
ethanol in mice. In the first study, mice were treated 
twice a week for five treatments with 2 mg ethyl 
carbamate/mouse (about 100 mg/kg body weight) by 
gastric intubation either in water or in 0.2 ml 40% 
ethanol. In the second study, mice were injected 
intraperitoneally with 10 mg ethyl carbamate/mouse 
(500 mg/kg body weight), again either in water or in 
0.2 ml 40% ethanol twice a week for 5 wk. In both 
studies, the presence of ethanol as a solvent enhanced 
pulmonary adenoma development, after 6 or 4 
months, respectively (the number of pulmonary ade-
nomas per mouse after 12 weeks was 13 [in water] and 
30 [in ethanol) in the second study). 
Ethyl carbamate carcinogenesis was also shown 
to be inftuenced by the Co-administration of other 
chemieals (N-acetylcysteine; deFlora et al., 1986) and 
by physical agents such as X-rays where, depending 
on the dose of X-rays co-administered, enhancement 
or reduction has been observed (see Mirvish, 1968). 
Various organs besides the mammary gland and 
the Jung are susceptible to ethyl carbamate tumour 
induction: . Iymphomas, vascular tumours, skin 
tumours, and hepatomas have been found. A com-
parison of tumour susceptibility among various 
organs of foetal, young and adult mice showed a high 
tumour susceptibility in rapidly proliferating and 
undifferentiated cells (Nomura, 1976). 
In almost all carcinogenicity studies, ethyl carba-
mate doses tested were well above the Saturation dose 
of the metabolizing enzyme system. The data pub-
lished by Yamamoto et a/. (1988) showed that the 
inhibition of ethyl carbama~e metabo1ism by acute 
ethanol administration did not open alternative 
metabolic pathways or markedly increase urinary 
- -II'\ 
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excretion. It seems reasonable, therefore, to assume 
that saturation of metabolism at high Ievels of ethyl 
carbamate does not Iead to a higher proportion of 
detoxication. Therefore, a single large dose could weil 
give rise to DNA darnage for a nurober of days and 
become equivalent to a subacute dosing regimen. 
Low-dose extrapolation and risk assessment 
The data summarized above clearly indicate that 
ethyl carbamate is a pluripotent carcinogen with 
respect to tumour induction in different species, 
organs, and stages of development of the animals. 
Animal studies require rather high dose Ievels for 
a tumour rate to become significantly increased. The 
lowest tumour incidence that can be assessed depends 
on the background tumour rate and on the number 
of animals used: to establish a 10% increase in 
tumour rate with a confidence Iimit of 95% in a 
population with a spontaneaus rate of 1 %, 40 
animals are needed. T o assess an increase in tumour 
rate of 1% or 0.1 %, 1100 or 80,000 animals per dose 
group would be needed. From this it is clear that the 
dose range of human exposure to ethyl carbamate in 
food and beverages (some 10 to 100 ng/kg body 
weight/day, which is four to five orders of magnitude 
below the doses needed for animal experimentation) 
is experimentally inaccessible and a corresponding 
tumour risk must be estimated. 
The FDA in the USA proposed the use of a single, 
very simple method for the risk assessment of car-
cinogens: a point on the dose-response curve is 
chosen where, in the judgement of the FDA, the 
data are still reliable, and a straight line is odrawn 
from that point through the origin ("linear-at-low-
dose, no-threshold model"; Crump, 1984; Lorentzen, 
1984). Using the linear-at-low-dose, no-threshold 
model, a lifetime risk Ievel of 1/106 is often considered 
to provide adequate protection (Rodricks, 1988). 
This risk Ievel is co1:1sidered to be negligible or 
insignificant and the corresponding dose Ievel may be 
called a "virtually safe dose". 
A linear extrapolation will be used below to calcu-
late such a virtually safe dose for ethyl carbamate. In 
view of the possibility that DNA-adduct formation 
represents the mechanism of tumour induction, a 
linear low dose-response curve appears to be appro-
priate (Lutz et al., 1990). 
Treatment of female rats with 12.5 mg ethyl carba-
mate/kg body weight/day resulted in an increased 
incidence of breast tumours of 24% (Table 1). With 
linear extrapolation to an incidence of one in a 
million, the dose required for this minute .. accept-
able" lifetime excess risk can be calculated to be 
53 ng/kg body weight/day. In female mice, the corre-
sponding figure is 69 ng/kg body weight/day. 
In mice, an additional major target organ is the 
Jung. Using the incidence induced by 12.5 mg/kg 
body weight (Table 1) and a linear extrapolation, a 
daily dose of 80 ng/kg body weight/day would result 
in one additional lung tumour in one million males 
exposed for lifetime. At 2.5 mg/kg body weight/day 
four Jung tumours were induced in male mice. Using 
this incidence for a linear extrapolation, a daily dose 
of 18 ng/kg body weight results. In females at 
12.5 mg/kg body weight, the corresponding dose is 
calculated tobe 41 ng/kg body weight/day. It follows 
that the breasts and lungs of NMRI mice are about 
equally susceptible to the carcinogenic activity of 
ethyl carbamate. 
The virtually safe dose Ievels for two organs and 
two animal species span a factor of only four to five. 
We therefore use these data with some confidence for 
a risk estimation in adult humans. Here, a daily 
burden of about 20 ng/kg body weight/day is reached 
under normal dietary habits, excluding alcoholic 
beverages. Individual habits may greatly increase the 
risk above the "widely accepted" Ievel: if 500 ml table 
wine are consumed daily, the risk is increased by a 
factor of up to five, relative to the above-mentioned 
risk under normal dietary habits. Regular drinking of 
20-40 ml stone-fruit brandies per day would raise the 
calculated tumour risk to near 1/104 • 
Ethyl carbamate is quite carcinogenic even after 
one application. If administered during early devel-
opment, typical single doses of I g/kg body weight 
give a high tumour incidence. With chronic adminis-
tration starting at the age of 8 weeks, a total admin-
istered dose of about 1 g/kg body weight resulted in 
much lower tumour induction (see Table 1). There-
fore, exposure to ethyl carbamate during foetal devel-
opment and early growth appears tobe more critical 
by about one order of magnitude. Consumption of 
stone·fruit brandy during pregnancy and breastfeed-
ing could, therefore, represent an unacceptable risk to 
the progeny not only because of the ethanol but also 
because of ethyl carbamate. 
We are aware of all the uncertainties in the risk 
assessment presented above. The combined knowl-
edge of mechanism, genotoxicity and carcinogenicity 
under many conditions indicates that ethyl carbamate 
has to be considered a potentially important human 
dietary carcinogen and its content in foodstuffs 
and beverages should be as low as possible. Since 
ethyl carbamate is formed by different processes in 
a variety of food items, the pertinent conditions 
of reaction and formation should be further 
investigated. 
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